DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Low dose of telmisartan (Drug); High dose of telmisartan (Drug); Low dose of losartan (Drug); High dose of losartan (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Boehringer Ingelheim


Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Clinical Details

Official title: 12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Changes in mean sitting valley value of DBP


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood

pressure (DBP) ≥ 95 and < 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) < 180 mmHg Exclusion Criteria:

- Not specified

Locations and Contacts

Additional Information

Starting date: July 2000
Last updated: October 20, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017